TG THERAPEUTICS, INC. financial data

Symbol
TGTX on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 27 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 395% % -11%
Quick Ratio 91% % 9.1%
Debt-to-equity 95% % -40%
Return On Assets 52% % 975%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 159,688,256 shares 1.7%
Common Stock, Shares, Outstanding 155,305,953 shares -0.34%
Entity Public Float $2,500,000,000 USD 0%
Common Stock, Value, Issued $159,000 USD 1.9%
Weighted Average Number of Shares Outstanding, Basic 144,316,786 shares -0.69%
Weighted Average Number of Shares Outstanding, Diluted 161,412,746 shares 0.67%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $616,287,000 USD 87%
Research and Development Expense $160,215,000 USD 70%
Costs and Expenses $492,963,000 USD 72%
Operating Income (Loss) $123,324,000 USD 194%
Nonoperating Income (Expense) $15,934,000 USD 2.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $107,390,000 USD 320%
Income Tax Expense (Benefit) $339,789,000 USD -15468%
Net Income (Loss) Attributable to Parent $447,179,000 USD 1812%
Earnings Per Share, Basic 3.1 USD/shares 1838%
Earnings Per Share, Diluted 2.77 USD/shares 1747%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $79,148,000 USD -56%
Cash, Cash Equivalents, and Short-term Investments $199,500,000 USD -36%
Accounts Receivable, after Allowance for Credit Loss, Current $305,628,000 USD 137%
Inventory, Net $125,586,000 USD 14%
Other Assets, Current $57,580,000 USD 266%
Assets, Current $630,764,000 USD 11%
Deferred Income Tax Assets, Net $348,000,000 USD
Property, Plant and Equipment, Net $66,000 USD -72%
Operating Lease, Right-of-Use Asset $6,278,000 USD -12%
Goodwill $799,000 USD 0%
Other Assets, Noncurrent $2,044,000 USD -1.4%
Assets $1,063,253,000 USD 84%
Liabilities, Current $153,760,000 USD 70%
Operating Lease, Liability, Noncurrent $7,021,000 USD -14%
Liabilities $415,233,000 USD 17%
Retained Earnings (Accumulated Deficit) $1,082,015,000 USD 29%
Stockholders' Equity Attributable to Parent $648,020,000 USD 191%
Liabilities and Equity $1,063,253,000 USD 84%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $28,715,000 USD -250%
Net Cash Provided by (Used in) Financing Activities $6,102,000 USD
Net Cash Provided by (Used in) Investing Activities $12,934,000 USD -40%
Common Stock, Shares Authorized 190,000,000 shares 0%
Common Stock, Shares, Issued 158,849,596 shares 1.7%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $47,751,000 USD -174%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $80,490,000 USD -56%
Interest Paid, Excluding Capitalized Interest, Operating Activities $6,143,000 USD 151%
Deferred Tax Assets, Valuation Allowance $39,977,000 USD -90%
Deferred Tax Assets, Gross $391,874,000 USD -6%
Operating Lease, Liability $8,065,000 USD -13%
Payments to Acquire Property, Plant, and Equipment $25,000 USD
Lessee, Operating Lease, Liability, to be Paid $10,536,000 USD -17%
Operating Lease, Liability, Current $1,044,000 USD -9.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,913,000 USD -8%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,080,000 USD -0.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.101 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,471,000 USD -26%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,827,000 USD -4.5%
Deferred Tax Assets, Operating Loss Carryforwards $275,710,000 USD -6.2%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,827,000 USD 0%
Operating Lease, Payments $500,000 USD -17%
Additional Paid in Capital $1,830,110,000 USD 4%
Depreciation, Depletion and Amortization $8,000 USD -72%
Deferred Tax Assets, Net of Valuation Allowance $348,000,000 USD
Share-based Payment Arrangement, Expense $55,100,000 USD 47%
Interest Expense $12,059,000 USD 16%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%